Improving Vectors for Delivering Gene Therapy May Help to Treat Hemophilia

Hemophilia is a genetic disorder which is caused by a missing or a defective clotting protein (factor VIII). The research team has improved the vectors for delivering the (human factor VIII) gene therapy to treat Hemophilia A.//

A recent study was found to examine 42 combinations of promotors and enhancers for human factor VIII (hfVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector before construction to take forward into development.

‘Improving vectors for delivering the human factor VIII gene therapy may help to treat Hemophilia.’

Tweet it Now

The evaluation of the different combinations in mice which may lack the factor VIII, demonstrated the significant and differing effects of the vector components which had on liver-specific expression of the hFVIII transgene.

The study results were reported in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

James M. Wilson, MD, PhD, Director of the Gene Therapy Program, Department of Medicine, University of Pennsylvania (Philadelphia, PA) and Editor, Human Gene Therapy Clinical Development, and coauthors from the University of Pennsylvania Department of Medicine and School of Nursing, and Dimension Therapeutics (Cambridge, MA), developed and compared the different AAV vectors to overcome the challenge of delivering the relatively large hFVIII gene and to achieve therapeutic levels of factor VIII gene expression.

Plant-made Therapy for Hemophilia Treatment
Hemophilia is an inherited disorder that impairs the ability to make blood clots. Plant-based therapy may show promise for treatment.

In the article entitled "Characterization of AAV-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice," the researchers also compared the levels of antibody generated against the various AAV transgene delivery vectors.

"Dr. Wilson's group and their colleagues at Dimension Therapeutics continue to improve the design of AAV vectors designed to treat the more common form of hemophilia, hemophilia A," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "These design improvements are crucial as the practical application of gene therapy for hemophilia progresses."

Source-Eurekalert